BusinessAGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR GeneBy Nasdaq OMXAug 10, 2017, 11:00 AM UTC
BusinessAgile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®By Nasdaq OMXJun 27, 2017, 12:00 PM UTC
BusinessNeos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years OldBy Nasdaq OMXJun 20, 2017, 1:47 AM UTC
BusinessAdamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017By Nasdaq OMXMay 2, 2017, 8:08 PM UTC
BusinessNeos Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare ConferenceBy Nasdaq OMXFeb 16, 2017, 12:30 PM UTC
BusinessAdamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's DiseaseBy Nasdaq OMXJan 6, 2017, 2:01 PM UTC
BusinessAdamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's DiseaseBy Nasdaq OMXJan 6, 2017, 2:01 PM UTC
BusinessNeos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHDBy Nasdaq OMXDec 20, 2016, 12:30 PM UTC
